Esophageal carcinoma (squamous + adeno) · line 1 · Weekly carboplatin + paclitaxel (CROSS-style chemo backbone)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-CARBOPLATIN-PACLITAXEL-WEEKLY`

ID	`IND-ESOPH-RESECTABLE-CROSS-NEOADJUVANT`
Type	Indication
Status	reviewed 2026-05-08 \| pending_clinical_signoff
Diseases	`DIS-ESOPHAGEAL`
Sources	`SRC-ESMO-ESOPHAGEAL-2024` `SRC-NCCN-ESOPHAGEAL-2025`

Notes

§17 phased indication (RATIFIED 2026-05-07). Free-text RT description in this `notes:` block has been replaced by structured `phases:` field with radiation_id=RC-CROSS-NEOADJ; the RadiationCourse owns the concurrent chemo regimen reference (concurrent_chemo_regimen=REG-CARBOPLATIN-PACLITAXEL-WEEKLY) per planning doc §2.3 (XOR rule on phase fields). The post-CROSS surgery phase (esophagectomy) is deferred to C4 chunk (#437) — this entity models the neoadjuvant CRT phase only. Backward-compat: legacy `recommended_regimen=REG-CARBOPLATIN-PACLITAXEL-WEEKLY` preserved so non-§17-aware render paths continue to surface the chemo backbone. Adjuvant nivolumab post-resection (CheckMate-577, ypT+ or ypN+) is a separate downstream indication and remains out of scope for this chunk.

Used By

Algorithms

ALGO-ESOPH-RESECTABLE-1L - ALGO-ESOPH-RESECTABLE-1L

Indication

IND-ESOPH-ADJUVANT-NIVOLUMAB-POST-CROSS - IND-ESOPH-ADJUVANT-NIVOLUMAB-POST-CROSS
IND-RECTAL-TNT-LONG-COURSE-PRODIGE23 - IND-RECTAL-TNT-LONG-COURSE-PRODIGE23
IND-RECTAL-TNT-SHORT-COURSE-RAPIDO - IND-RECTAL-TNT-SHORT-COURSE-RAPIDO